After nebulizer flop, Verona touts interim PhII results on another version of its lead COPD drug
Chalk up a much-needed — if preliminary — win for Verona Pharma in its multi-pronged effort to tackle COPD.
The London-based respiratory drug developer is reporting that …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
